Gaurav Munj 2022-03-04T06:42:16+00:00 Press Releases Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Governance Documents Committees Year None20232022 September 14, 2023 Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy September 5, 2023 Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies July 31, 2023 Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy July 31, 2023 Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments July 27, 2023 Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates May 31, 2023 Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day May 25, 2023 Biohaven to Present R&D Day at Yale School of Management May 12, 2023 Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments April 17, 2023 Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy March 23, 2023 Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments Current page 1 Page 2 ► ► Displaying 1 - 10 of 14 BIOHAVEN (BHVN) Volume Market Cap 52 Week High 52 Week Low Data Provided by Refinitiv. Minimum 15 minutes delayed.
Year None20232022 September 14, 2023 Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy September 5, 2023 Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies July 31, 2023 Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy July 31, 2023 Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments July 27, 2023 Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates May 31, 2023 Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day May 25, 2023 Biohaven to Present R&D Day at Yale School of Management May 12, 2023 Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments April 17, 2023 Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy March 23, 2023 Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments Current page 1 Page 2 ► ► Displaying 1 - 10 of 14
September 14, 2023 Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
September 5, 2023 Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies
July 31, 2023 Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
July 31, 2023 Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
July 27, 2023 Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
May 31, 2023 Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
May 12, 2023 Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
April 17, 2023 Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy
March 23, 2023 Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
